• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center.

作者信息

Zeb Lawangeen, Mhaskar Rahul, Lewis Suzanna, Patel Nishit S, Sadhwani Divya, Patel Nupur, Ekhlassi Erfon, Lu Yuanyuan, Seminario-Vidal Lucia

机构信息

Department of Dermatology and Cutaneous Surgery, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.

Department of Internal Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.

出版信息

Dermatol Ther. 2021 Mar;34(2):e14826. doi: 10.1111/dth.14826. Epub 2021 Feb 12.

DOI:10.1111/dth.14826
PMID:33527682
Abstract
摘要

相似文献

1
Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center.学术中心中银屑病患者使用生物制剂和阿普米拉斯的真实世界药物留存率及治疗中断原因
Dermatol Ther. 2021 Mar;34(2):e14826. doi: 10.1111/dth.14826. Epub 2021 Feb 12.
2
Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.阿普米司特联合生物制剂治疗生物制剂治疗应答不佳的银屑病患者。
J Dermatol. 2020 Mar;47(3):290-294. doi: 10.1111/1346-8138.15193. Epub 2019 Dec 22.
3
Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.初治生物制剂的银屑病患者开始使用阿普米司特或生物制剂的真实世界治疗模式及医疗费用
J Med Econ. 2019 Apr;22(4):365-371. doi: 10.1080/13696998.2019.1571500. Epub 2019 Feb 4.
4
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.真实世界中生物制剂初治患者应用阿普司特或生物制剂治疗银屑病的美国医疗成本。
J Comp Eff Res. 2019 Jan;8(1):45-54. doi: 10.2217/cer-2018-0097. Epub 2018 Nov 2.
5
Real-world use of apremilast for patients with psoriasis in Japan.日本银屑病患者阿普米司特的真实世界应用。
J Dermatol. 2018 Nov;45(11):1345-1348. doi: 10.1111/1346-8138.14617. Epub 2018 Aug 31.
6
Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting.在真实世界中，合并症负担和既往生物制剂暴露情况可能预测阿普米拉斯治疗银屑病的药物留存率。
Dermatol Ther. 2020 Nov;33(6):e14168. doi: 10.1111/dth.14168. Epub 2020 Sep 13.
7
Real-World Experience With Apremilast in Treating Psoriasis.阿普米拉斯治疗银屑病的真实世界经验。
J Cutan Med Surg. 2017 Mar/Apr;21(2):145-151. doi: 10.1177/1203475416676030. Epub 2016 Oct 23.
8
Apremilast and biologics: Characteristics of patients treated with apremilast before, during, or after a biological treatment.阿普米司特和生物制剂：在接受生物制剂治疗之前、期间或之后使用阿普米司特治疗的患者的特征。
Dermatol Ther. 2022 Nov;35(11):e15844. doi: 10.1111/dth.15844. Epub 2022 Oct 7.
9
Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis.真实世界中阿普米司特治疗日本斑块状银屑病患者的疗效和安全性数据。
J Dermatolog Treat. 2019 Jun;30(4):383-386. doi: 10.1080/09546634.2018.1525480. Epub 2018 Oct 8.
10
Drug survival of apremilast in patients treated for psoriasis in a real-world setting.在真实临床环境中接受治疗的银屑病患者中阿普米司特的药物留存率
J Am Acad Dermatol. 2018 Oct;79(4):760-761. doi: 10.1016/j.jaad.2018.03.028. Epub 2018 Mar 26.

引用本文的文献

1
Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry.真实世界中博乐达单抗治疗中重度斑块状银屑病患者的疗效数据：来自捷克共和国 BIOREP 登记处的观察性研究。
Adv Ther. 2024 Oct;41(10):3951-3971. doi: 10.1007/s12325-024-02952-4. Epub 2024 Aug 29.
2
Apremilast Survival and Reasons for Discontinuation in Psoriasis: Five-Year Experience From a Greek Tertiary Care Centre.阿普米拉斯在银屑病中的生存率及停药原因：来自希腊三级护理中心的五年经验
Dermatol Pract Concept. 2022 Jan 1;12(2):e2022076. doi: 10.5826/dpc.1202a76. eCollection 2022 May.
3
Survival of biological therapeutics in psoriasis: retrospective analysis of 3-years data in a Turkish registry, PSORTAKSIS.
银屑病生物治疗的生存情况：土耳其注册研究 PSORTAKSIS 的 3 年回顾性分析。
Turk J Med Sci. 2022 Feb;52(1):58-66. doi: 10.3906/sag-2104-339. Epub 2022 Feb 22.